-+ 0.00%
-+ 0.00%
-+ 0.00%

Eledon’s Tegoprubart Improves Quality of Life Versus Tacrolimus in Phase 2 Kidney Transplant Trial

PUBT·10/26/2026 11:08:26
Listen to the news
Eledon’s Tegoprubart Improves Quality of Life Versus Tacrolimus in Phase 2 Kidney Transplant Trial
  • Eledon Pharmaceuticals announced Phase 2 BESTOW trial results showing sustained quality-of-life benefits with investigational tegoprubart versus tacrolimus in kidney transplant recipients.
  • Tegoprubart reduced transplant-related symptom burden through 12 months; tacrolimus recipients reported slightly worse symptom occurrence than at baseline.
  • Quality-of-life improvements included clinically and statistically significant benefits in symptoms and problems compared with tacrolimus.
  • Results were presented Oct. 23, 2026, at the American Society of Nephrology Kidney Week meeting in Denver.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852807) on October 26, 2026, and is solely responsible for the information contained therein.